Economic analysis of use of counterfeit drugs: health impairment risk of counterfeit phosphodiesterase type 5 inhibitor taken as an example
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The size of the market for counterfeit drugs throughout the world is considerable. Many cases of health impairment due to counterfeits have been reported. The market share of counterfeits in drug markets in developed countries is smaller than that in developing countries. However, the size of the market for counterfeits of phosphodiesterase type 5 inhibitors (PDE5Is) used as anti-erectile-dysfunction drugs is not small. The purpose of the present study was to analyze the health impairment risk of taking the counterfeit PDE5Is and the convenience of obtaining the counterfeits in Japan, using an economic methodology in order to work out countermeasures for reducing the health impairment risk.
Information was obtained by interviewing employees of pharmaceutical and chemical corporations in Japan.
Results and discussion
The size of the market for counterfeit PDE5Is in Japan was recently estimated to be about 2.5 times larger than that of genuine PDE5Is. The price of the counterfeits in their market is reported to be nearly equal to that of the genuine PDE5Is. An outbreak of severe hypoglycemia among users of counterfeit PDE5Is containing an antidiabetic drug in Singapore was reported in 2008, and seven patients remained comatose as a result of prolonged neuroglycopenia. Four of them subsequently died, so the health impairment risk due to counterfeit PDE5Is should not be ignored. In order to obtain a genuine PDE5I in Japan, a patient must be examined and have a prescription written at a medical institution, and buy it at a dispensing pharmacy. Focusing on the health impairment risk due to counterfeit PDE5Is and the convenience of obtaining the counterfeits in Japan, we analyzed the effects on the prices and quantities of PDE5Is in the market from demand and supply curves, using an economic methodology. From the analysis, it was shown that the health impairment risk due to the counterfeits is underestimated in the market in Japan. Physicians should warn their patients not to buy counterfeit PDE5Is, and when they write a prescription for purchasing genuine PDE5Is, should inform their patients of the severe health problems that occurred in Singapore.
The present economic analysis indicates that the health impairment risk due to counterfeit PDE5Is is underestimated in the market in Japan. Clarification of the underestimation of the severe health impairment risk due to counterfeits is important.
- World Health Organization. How does WHO define a counterfeit drug (medicine)? 2005. http://www.who.int/medicines/services/counterfeit/faqs/05/en/.
- World Health Organization. International Medical Products Anti-Counterfeiting Taskforce (IMPACT). 2006. http://www.who.int/medicines/services/counterfeit/faqs/count_q-a/en/.
- World Health Organization. Counterfeit medicines: Key facts. 2009. http://www.who.int/medicines/services/counterfeit/CfeitsFactSheetJuly09.pdf.
- Pitts PJ. 21st Century International Drug Terrorism. Testimony by CMPI Director, Peter J. Pitts, to the Government Reform Committee Subcommittee on Criminal Justice, Drug Policy and Human Resources. 2005. http://special.pacificresearch.org/pub/sab/health/2005/21_Century_Counterfeiting_Testimony.pdf.
- Venhuis BJ, Barends DM, Zwaagstra ME, de Kaste D. Recent developments in counterfeits and imitations of Viagra, Cialis and Levitra: a 2005–2006 update. RIVM Report 370030001. 2007. http://www.rivm.nl/bibliotheek/rapporten/370030001.pdf.
- Forzley M. Counterfeit goods and the public’s health and safety. International Intellectual Property Institute (IIPI). 2003. http://www.iipi.org/reports/Counterfeit_Goods.pdf.
- Kao SL, Chan CL, Tan B, Lim CC, Dalan R, Gardner D, et al. An unusual outbreak of hypoglycemia. N Engl J Med. 2009;360:734–6. CrossRef
- Sugita M. Risk analysis for health impairment due to the use of counterfeit drugs in Japan using phosphodiesterase type 5 inhibitor (PDE5I) as an example. Nohon Seikino Gakkai-zasshi (Jpn J Sex Med). 2008;23:299–309 (in Japanese with English abstract).
- Pfizer Japan Inc. Adoption of technology of radio frequency identification (RFID) by Pfizer Japan Inc: for health of patients against counterfeit Viagra: technology against counterfeits suppliers. 2006 (in Japanese).
- Pfizer Japan Inc. Dangerous counterfeit Viagra. 2008 (in Japanese) http://www.ed-info.net/health.html.
- Ogasawara N. Forged medicines and its preventive measures. Nihon Hoso Gakkai-shi (J Packag Sci Technol Jpn). 2007;16:367–75 (in Japanese).
- Kimura K. Risk by counterfeit medicines which spread globally. Pfizer Forum. 2007;100 (in Japanese) http://www.pfizer.co.jp/pfizer/healthcare/pfizer_forum/2007/n100.html.
- Bayer Yakuhin Ltd. Information on an acceptance of an application for prohibiting counterfeits of Levitra®, medicine for erectile dysfunction. 2006 (in Japanese) http://byl.bayer.co.jp/scripts/pages/jp/press_release/press_detail/?file_path=2006%2Fnews2006-12-18.html.
- Eli Lilly Japan Ltd. Be careful about counterfeits of Cialis®: Additional information about an attention to “ED care support” on a website. 2008 (in Japanese) http://www.lilly.co.jp/CACHE/news_2008_13.cfm.
- Sankei Shimbun Co Ltd. Kamagra. Yukan Fuji. 28 Oct 2008 (in Japanese).
- Yakuji Nippo Ltd. Viagra: Half of drugs imported privately are counterfeits. Yakuji Nippo. 1 Dec 2006 (in Japanese) http://www.yakuji.co.jp/entry1744.html.
- Mainichi Newspapers Co Ltd. Internet retailing of counterfeit “Viagra.” Mainichi Newspaper (Osaka version) morning edition, 20 Mar 2007. p. 23 (in Japanese).
- Nagoya Customs, Japan. Situation of crackdown on violation of Customs Law at Nagoya Customs, Japan in 2008. 2009 (in Japanese) http://www.customs.go.jp/nagoya/content/H20tekihatu_nagoya.pdf.
- Cleaver T. Economics: the basics. London: Routledge; 2004.
- Stiglitz JE, Walsh CE. Economics. 4th ed ed. New York: Norton; 2006.
- Black J, Hashimzade N, Myles G. A dictionary of economics. 3rd ed ed. Oxford: Oxford University Press; 2009.
- Tsuchida S. Risk perception and risk communication: The Society for Risk Analysis, Japan. Nihon Eisei Gakkai-zasshi (Jpn J Hyg). 2007;62:325–6 (in Japanese).
- Arrow KJ. Uncertainty and the welfare economics of medical care. Am Econ Rev. 1963;58:941–73.
- Akerlof G. The market for lemons: quality uncertainty and the market mechanism. Q J Econ. 1970;84:488–500. CrossRef
- Shiozawa S. An introduction to economics. Tokyo, Yuhikaku. 1996 (in Japanese).
- Goto R, Takahashi Y, Nishimura S, Ida T. A cohort study to examine whether time and risk preference is related to the success of smoking cessation? Addiction. 2009;104:1018–24. CrossRef
- Economic analysis of use of counterfeit drugs: health impairment risk of counterfeit phosphodiesterase type 5 inhibitor taken as an example
Environmental Health and Preventive Medicine
Volume 15, Issue 4 , pp 244-251
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- PDE5 inhibitor
- Health impairment risk
- Convenience of acquisition
- Economic analysis